US2012142544A1PendingUtilityA1
Diagnostic transcriptomic biomarkers in inflammatory cardiomyopathies
Est. expiryJun 2, 2029(~2.9 yrs left)· nominal 20-yr term from priority
C12Q 2600/136C12Q 2600/158C12Q 1/6883C12Q 2600/112
39
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.
Claims
exact text as granted — not AI-modified1 . A transcriptomic biomarker for the identifying patients at risk of developing myocarditis or idiopathic dilated cardiomyopathy, or the diagnosis and differentiation between myocarditis and idiopathic dilated cardiomyopathy comprising one or more marker signatures, wherein the marker signatures are set forth as:
marker signature I: (1552302_at) FLJ77644.TMEM106, (1552553_a_at) NLRC4, (1552584_at) IL12RB1, (1554899_s_at) FCER1G, (1555349_a_at) ITGB2, (1559584_a_at) C16orf54, hCG — 1644884, (1563245_at) MGST1, (1565162_s_at) ANXA2, (1568126_at) SPP1, (1568574_x_at) IFI30, (201442_at) CTSC, (201487_at) LAPTM5, (201721_s_at) CD14, (201743_at) CAPG, (201850_at) PLTP, (202075_s_at) VAMP8, (202546_at) LYN, (202625_at) ITGB2, (202803_s_at) PCK2, (202847_at) CSF1R, (203104_at) RASSF2, (203185_at) RPS6KA1, (203379_at) CD53, (203416_at) PLEK, (203471_s_at) SEMA4D, (203528_at) CD163, (203645_s_at) PLA2G2A, (203649_s_at) CXCL9, (20391_s_at) CYBB, (203923_s_at) IRF8, (204057_at) CD48, (204118_at) TYROBP, (204122_at) GLIPR1, (204222_s_at) FCER1G, (204232_at) PLEKHO2, (204436_at) CD44, (204490_s_at) SLC7A7, (204588_s_at) STC1, (204595_s_at) CD52, (204661_at) VSIG4, (204787_at) IL10RA, (204912_at) SASH3, (204923_at) TLR2, (204924_at) CSTA, (20497 l_at) CCR1, (205098_at, 205269_at) LCP2, (205270_s_at) GZMA, (205488_at) CD86, (205685_at) CD8A, (205758_at) ITGAM, (205786_s_at) LY86, (205859_at) PTPN6, (206687_s_at) CCR2, FLJ78302, (206978_at) PTPRC, (207238_s_at) SYK, (207540_s_at) LILRB2, (207697_x_at) LCP1, (208885_at) CORO1A, (209083_at) HLA-DQB1, (209480_at) DLK1, (209560_s_at) CD44, (209835_x_at) SPP1, (209875_s_at) AIF1, (209901_x_at) C3AR1, (209906_at) CD300A, (209933_s_at) NCF2, (209949_at) LILRB2, (210146_x_at) TLR1, (210176_at) LAIR1, (210644_s_at) LILRB1, (211336_x_at) TRBC1, TRBC2, TRBV19; (211796_s_at) CD44, (212063_at) PTPRC, (212587_s_at, 212588_at) HLA-DQA1 HLA-DQA2; (212671_s_at) hCG — 1998957, HLA-DQB1/B2, HLA-DRB1/2/3/4/5; (21299_x_at) AIF1, (213095_x_at) DOCK2, (213160_at) HSPA6, (213418_at) RNASE6, (213566_at) RAC2, (213603_s_at) MYO1F, (213733_at) HLA-DQA1, (213831_at) LYZ, (213975_s_at) LOC648998, (214084_x_at) CD163, (215049_x_at) AIF1, (215051_x_at) ADA, (216705_s_at) FCGR1A, FCGR1C; (216950_s_at) GLUL, (217202_s_at) SNX10, (218404_at) MAFB, (218559_s_at) CCDC109B, (218802_at) BIN2, (219191_s_at) DOCK10, (219279_at) SLAMF8, (219386_s_at) SIGLEC1, (219519_s_at) 1-Mar, (219574_at) MS4A4A, (219607_s_at) MS4A6A, (219666_at) GAL3ST4, (219815_at) PSTPIP2, (219938_s_at) TLR7, (220146_at) COTL1, (221059_s_at) NPL, (221210_s_at) SH3BGRL3, (221269_s_at) PYCARD, (221666_s_at) CLEC7A, (221698_s_at) OBFC2A, (222872_x_at) CENTA2, (222876_s_at, 223343_at) MS4A7, (223344_s_at, 223343_at) MS4A6A, (224356_x_at) MS4A4A, (224357_s_at) COTL1, (224583_at) BCAT1, (225285_at) C1QC, (225353_s_at) CTSC, (225646_at) CTSC, (225647_s_at) BCAT1, (226517_at, 226818_at) MPEG1, (226841_at) FYB, (227266_s_at) RILPL2, (227983_at) OSR1, (228399_at) C1 orf162, (228532_at) LILRB1, (230741_at) MRO, (231358_at) CTSS, (232617_at) DOCK8, (232843_s_at) OBFC2A, (233085_s_at) PARVG, (234987_at) CPM, (235019_at) HAVCR2, (235458_at) CCL18, (32128_at) CD52, (34210_at) MAFF, (36711_at) SIGLEC1; or marker signature: (1552411_at) DEFB106A/B, (1556721_at) FLJ33706, (1559224_at) LCE1E, (1562256 at, 1562257_x_at) NLRP1, (1562785_at) HERC6, (1564281_at) LOC285708, (1564362_x_at) ZNF843, (1569568_at) NA, (1569569_x_at) NA, (213609_s_at) SEZ6L, (213791_at) PENK, (224209_s_at) GDA, (231628_s_at) NA, (243909_x_at) GUSBL2, (244891_x_at) NA; or marker signature II: (1552411_at) DEFB106A/B, (1556721_at) FLJ33706, (1559224_at) LCE1E, (1562256_at, 1562257_x_at) NLRP1, (1562785_at) HERC6, (1564281_at) LOC285708, (1564362_x_at) ZNF843, (1569568_at) NA, (1569569_x_at) NA, (213609_s_at) SEZ6L, (213791_at) PENK, (224209_s_at) GDA, (231628_s_at) NA, (243909_x_at) GUSBL2, (244891_x_at) NA; or, marker signature III: MafB, MafF, MHC class II, CD44, BCAT1 ( Homo sapiens ); CCR2, BCAT1, ADA, Annexin II, Pleckstrin ( Homo sapiens ); p17-phox, CCR2, p67-phox, Pleckstrin, IL-12 receptor ( Homo sapiens ); C1q, CD44, CD14, SLAP-130(ADAP), alpha-4/beta-1 integrin ( Homo sapiens ); Plastin, IRT-1 ( Homo sapiens ); CD163, HP/HB complex ( Homo sapiens ); Complement component C1, Complement C4=Complement component C4a + , Complement component C4b, Complement C2=Complement component C2a + , Complement component C2b, PLTP, ABCA1, CREB1, Cholesterol extracellular region, Cholesterol+ATP+H 2 O=Cholesterol+ADP+PO 4 3− ( Homo sapiens ); or, marker signature IV: (156328_at) NA, (204477_at) RABIF, (205275_at) GTPBP1, (214313_s_at) EIF5B; or, marker signature V: (1552302_at) FLJ77644, TMEM106A; (1552310_at) C15orf40, (1553212_at) KRT78, (1555349_a_at) ITGB2, (1555878_at) RPS24, (1556033_at) NA, (1556507_at) NA, (1558605_at) NA (1559224_at) LCE1E, (1562785_at) HERC6, (1565662_at) NA, (15658300 NA, (202375_at) SEC24D, (202445_s_at) NOTCH2, (203741_s_at) ADCY7, (204222_s_at) GLIPR1, (206052_s_at) SLBP, (206333_at) MSI1, (206770_s_at) SLC35A3, (209307_at) SWAP70, (211089_s_at) NEK3, (211341_at) LOC100131317, POU4F1; (212511_at) PICALM, (212830_at) MEGF9, (212999_x_at) hCG — 1998957, HLA-DQB1/2, HLA-DRB1/2/3/4/5; (213501_at) ACOX1, (213831_at) HLA-DQA1, (217054_at) NA, (217182_at) MUC5AC, (217322_x_at) NA, (217777_s_at) PTPLAD1, (218803_at) CHFR, (219425_at) SULT4A1, (221663_x_at) HRH3, (223077_at) TMOD3, (224327_s_at) DGAT2, (224996_at) Na, (225579_at) PQLC3, (226240_at) MGC21874, (227280_s_at) CCNYL1, (227618_at) Na, (227983_at) RILPL2, (228980_at) RFFL, (229191_at) TBCD, (230836_at) ST8SIA4, (231599_x_at) DPF1, (234495_at) KLK15, (234986_at) NA, (234987_at) NA, (236232_at) STX4, (236404_at) NA, (236698_at) NA, (238327_at) LOC440836, (238445_x_at) MGAT5B, (239463_at) NA, (242383_at) NA, (242563_at) NA, (243819_at) NA, (244841_at) SEC24A, (32069_at) N4BP1, (44673_at) SIGLEC1, (53720_at) C19orf66; or, marker signature VI: MSI1 (1556507_at), KRT78, KRT78 (1556507_at), KRT78 (1556507_at), 1556507_at; combinations, complementary sequences, fragments, alleles, variants, or gene products thereof.
2 . The transcriptomic marker of claim 1 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
3 . A transcriptomic biomarker for the diagnosis between giant cell myocarditis and idiopathic dilated cardiomyopathy comprising a marker signature set forth as: (210667_at) AQP4, (221212_x_at) PBRM1, (227145_at) LOXL4, (228329_at) DAB1, (231577_s_at) GBP1, (231906_at) HOXD8, (235334_at) ST6GALNAC3, (237783_at) PLAC8L1, complementary sequences, fragments, alleles, variants and gene products thereof.
4 . The transcriptomic marker of claim 3 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
5 . A transcriptomic biomarker for the diagnosis between sarcoidosis and idiopathic dilated cardiomyopathy comprising a marker signature set forth as: (1552974_at) NA, (1553781_at) ZC3HAV1L, (1554478_a_at) HEATR3, (1556760_a_at) NA, (1556883_a_at) LOC440896, (1557717_at) LOC338862, (1560144-at) NA, (1560683_at) BCL8, (1560684_x_at) BCL8, (1561543_at) NA, (1562035_at) NA, (1563054_at) NA, (1563452_at) KIAA0241, (1564107_at) NA, (1564733_at) NA, (1565788_at) NA, (1566550_at) NA, (1568589_at) NA, (201291_s_at) TOP2A, (204666_s_at) RP5-1000E10.4, (208356_s_at) BCL2L11, (209371_s_at) SH3BP2, (215512_at) 6-Mar, (216947_a) DES, (217292_at) MTMR7, (218554_s_at) ASH1L, (218585_s_at) DTL, (219528_at) TIPIN (219735_s_at) TFCP2L1, (219918_s_at) ASPM, (220085_at) HELLS, (220735_s_at) SENP7, (220930_s_at) MGC5590, (221212_x_at) PBRM1, (221268_s_at) SGPP1, (221969_at) NA, (223700_at) MND1 (223865_at) SOX6, (224424_x_at) LOC440888, (224426_s_at) LOC440888, (232453_at) NA, (233786_at) NA, (235588_at) ESCO2, (235661_at) NA, (235899_at) CA13, (236628_at) NA, (236470_at) NA, (237289_at) CREB1, (238370_x_at) RPL22, (238375_at, 239486_at) NA, (239899_at) RNF145, (241922_at) NA, (242784_at) NA, (242939_at) TFDP1, (244356_at) NA, (244609_at) NA, (37892_at) COL11A1, complementary sequences, fragments, alleles, variants and gene products thereof.
6 . The transcriptomic marker of claim 5 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
7 . A transcriptomic biomarker for the diagnosis between peripartum cardiomyopathy and idiopathic dilated cardiomyopathy comprising a marker signature set forth as: (1553972_a_at) CBS, (1557833_at) NA, (1560395_at) NA; (201909_at) LOC100133662, RPS4Y1; (204409_s_at, 204410_at) EIF1AY, (205000_at, 205001_s_at) DDX3Y; (205033_s_at) DEFA1, DEFA3, LOC728358; (205048_s_at) PSPH, (205609_at) ANGPT1, (206624_at) LOC100130216, USP9Y; (206700_s_at) JARID1D, (207063_at) CYorf14, (208067_x_at) LOC100130224, UTY; (209771_x_at) CD24, (211018_at) LSS, (211149_at) LOC100130224, UTY; (212768_s_at) OLFM4, (212816_s_at) CBS, (212906_at) GRAMD1B, (214131_at) CYorf15B, (214218_s_at) XIST, (214983_at) TTTY15, (216758_at) NA, (219938_s_at) PSTPIP2, (221728_x_at) XIST, (223645_s_at, 223646_s_at) CYorf15B, (224293_at) TTTY10, (224588_at, 224589_at, 224590_at, 227671_at) XIST, (227742_at) CLIC6, (228194_s_at) SORCS1, (228492_at) LOC100130216, USP9Y; (221960_at) MUM1L1, (229534_at) ACOT4, (230104_s_at) TPPP, (230760_at) LOC100130829, ZFY; (231592_at) TSIX, (232365_at) SIAH1, (232618_at) CYorf15A, (233176_at) NA, (235334_at) ST6GALNAC3, (235446_at) NA, (235942_at) LOC401629, LOC401630, (236694_at) CYorf15A, (239568_at) PLEKHH2, (239584_at) NA, (239677_at) NA, (24316_at) NA, (243610_at) C9orf135, (244482_at) Na, (226_s_at) CD24, complementary sequences, fragments, alleles, variants and gene products thereof.
8 . The transcriptomic marker of claim 7 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
9 . A transcriptomic biomarker for the diagnosis between systemic lupus erythematosus and idiopathic dilated cardiomyopathy comprising a marker signature set forth as: (1552946_at) ZNF114, (1553607_at) C21orf109, (1555485_s_at) FAM153B, (1558882_at) LOC401233, (1561012_at) NA, (1566518_at) NA, (1569539_at) NA, (1569794_at) NA, (207781_s_at) ZNF711, (222375_at) NA, (229288_at) NA, (229523_at) TTMA, (235803_at) NA, (238553_at) EPHA7, (238755_at) NA, (240783_at) NA, (240903_at) NA, (242641_at) NA, (243012_at) NA, (244626_at) NA, (244636_at) NA, complementary sequences, fragments, alleles, variants and gene products thereof.
10 . The transcriptomic marker of claim 9 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
11 . A transcriptomic biomarker for the diagnosis between giant cell myocarditis and lymphocytic myocarditis comprising the marker signature set forth as: (156328_at) NA, (204477_at) RABIF, (205275_at) GTPBP1, (214313_s_at) EIF5B, complementary sequences, fragments, alleles, variants and gene products thereof.
12 . The transcriptomic marker of claim 11 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
13 . A transcriptomic biomarker for the diagnosis between sarcoidosis and lymphocytic myocarditis comprising a marker signature set forth as: (20447_at) RABIF, (205275_at) GTPBP1, (214313_s_at) EIF5B, (224500_s_at) MON1A, (236093_at) NA, (243564_at) PDE1C, complementary sequences, fragments, alleles, variants and gene products thereof.
14 . The transcriptomic marker of claim 13 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
15 . A transcriptomic biomarker for the diagnosis between peripartum cardiomyopathy and lymphocytic myocarditis comprising a marker signature set forth as: (156328_at) NA, (205275_at) GTPBP1, (207300_s_at) F7, (214313_s_at) EIF5B, (214473_x_at) PMS2L3, (227509_x_at) NA, (228232_s_at) VSIG2, (230731_x_at) ZDHHC8, (232586_x_at) LOC100133315, (236093_at) NA, (237867_s_at) PID1, (243564_at) PDE1C, complementary sequences, fragments, alleles, variants and gene products thereof.
16 . The transcriptomic marker of claim 15 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
17 . A transcriptomic biomarker for the diagnosis between systemic lupus erythematosus and lymphocytic myocarditis comprising a marker signature set forth as: (1556205_at) NA, (202179_at) BLMH, (203134_at) PICALM, (203540_at) GFAP, (205554_s_at) DNASE1L3, (205673_s_at) ASB9, (205794_s_at) NOVA1, (209220_at) GPC3, (209304_x_at) GADD45B, (209540_at) IGF1, (209923_s_at) BRAP, (212173_at) AK2, (213469_at) LPPR4 (214338_at) DNAJB12, (216269_s_at) ELN, (217950_at) NOSIP, (218180_s_at) EPS8L2, (220117_at) ZNF385D, (220941_s_at) C21orf91, (222002_at) C7orf26, (222879_s_at) POLH, (223574_x_at) PPP2R2c, (223586_at) ARNTL2, (230974_at) DDX19B, (233298_at) C13orf38, SOHLH2; (238151_at) NA, (243076_x_at) GLI4, complementary sequences, fragments, alleles, variants and gene products thereof.
18 . The transcriptomic marker of claim 17 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
19 . A transcriptomic biomarker for the differential diagnosis between giant cell myocarditis and sarcoidosis comprising a marker signature set forth as: (1553894_at) CCDC122, (1557311_at) LOC100131354, (1557996_at) POLR2J4, (1558430_at) NA, (1559227_s_at) VHL, (1561789_at) NA, (1569312_at) NA, (205238_at) CXorf34, (211734_s_at) FCER1A, (218699_at) RAP2C, (225207_at) PDK4, (231114_at) SPATA22, (231418_at) NA, (231819_at) NA, (231956_at) KIAA1618, (233927_at) NA, (239151_at) CTGLF6, (241788_x_at) NA, (242691_at) NA, complementary sequences, fragments, alleles, variants and gene products thereof.
20 . The transcriptomic marker of claim 19 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
21 . A transcriptomic biomarker for the diagnosis of myocarditis comprising a marker signature set forth as: (1552302_at) FLJ77644, TMEM106A; (1552310_at) C15orf40, (1553212_at) KRT78, (1555349_a_at) ITGB2, (1555878_at) RPS24, (1556033_at) NA, (1556507_at) NA, (1558605_at) NA (1559224_at) LCE1E, (1562785_at) HERC6, (1565662_at) NA, (1565830_at) NA, (202375_at) SEC24D, (202445_s_at) NOTCH2, (203741_s_at) ADCY7, (204222_s_at) GLIPR1, (206052_s_at) SLBP, (206333_at) MSI1, (206770_s_at) SLC35A3, (209307_at) SWAP70, (211089_s_at) NEK3, (211341_at) LOC100131317, POU4F1; (212511_at) PICALM, (212830_at) MEGF9, (212999_x_at) hCG — 1998957, HLA-DQB1/2, HLA-DRB1/2/3/4/5 (213501_at) ACOX1, (213831_at) HLA-DQA1, (217054_at) NA, (217182_at) MUC5AC, (217322_x_at) NA, (217777_s_at) PTPLAD1, (218803_at) CHFR, (219425_at) SULT4A1, (221663_x_at) HRH3, (223077 2 A) TMOD3, (224327_s_at) DGAT2, (224996_at) Na, (225579_at) PQLC3, (226240_at) MGC21874, (227280_s_at) CCNYL1, (227618_at) Na, (227983_at) RILPL2, (228980_at) RFFL, (229191_at) TBCD, (230836_at) ST8SIA4, (231599_x_at) DPF1, (234495_at) KLK15, (234986_at) NA, (234987_at) NA, (236232_at) STX4, (236401 at NA, (236698_at) NA, (238327_at) LOC440836, (238445_x_at) MGAT5B, (239463_at) NA, (242383_at) NA, (242563_at) NA, (243819_at) NA, (244841_at) SEC24A, (32069_at) N4BP1, (44673_at) SIGLEC1, (53720_at) C19orf66, complementary sequences, fragments, alleles, variants and gene products thereof.
22 . The transcriptomic marker of claim 21 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
23 . A transcriptomic biomarker for the diagnosis of myocarditis versus idiopathic dilated cardiomyopathy comprising a marker signature set forth as: MSI1 (1556507_at), KRT78, KRT78 (1556507_at), KRT78 (1556507_at), 1556507_at, complementary sequences, fragments, alleles, variants and gene products thereof.
24 . The transcriptomic marker of claim 23 , wherein nucleic acids or peptides thereof, in the marker signature are differentially expressed as compared to controls.
25 . A transcriptomic biomarker for the diagnosis of subtypes of inflammatory cardiomyopathy versus idiopathic dilated cardiomyopathy comprising marker signatures set forth in Table 18, complementary sequences, fragments, alleles, variants and gene products thereof.
26 . A transcriptomic biomarker for the diagnosis of rare types of inflammatory cardiomyopathy versus lymphocytic myocarditis comprising one or more marker signatures set forth in Tables 1 to 19, complementary sequences, fragments, alleles, variants and gene products thereof.
27 . A transcriptomic biomarker for the diagnosis of patients at risk of developing one or more cardiac disorders comprising one or more marker signatures set forth as:
marker signature I: (1552302_at) FLJ77644, TMEM106, (1552553_a_at) NLRC4, (1552584_at) IL12R131, (1554899_s_at) FCER1G, (1555349_a_at) ITGB2, (1559584_a_at) C16orf54, hCG — 1644884, (1563245_at) MGST1, (1565162_s_at) ANXA2, (1568126_at) SPP1, (1568574_x_at) IFI30, (201442_at) CTSC, (201487_at) LAPTM5, (201721_s_at) CD14, (201743_at) CAPG, (201850_at) PLTP, (202075_s_at) VAMP8, (202546_at) LYN, (202625_at) ITGB2, (202803_s_at) PCK2, (202847_at) CSF1R, (203104_at) RASSF2, (203185_at) RPS6KA1, (203379_at) CD53, (203416_at) PLEK, (203471 is at) SEMA4D, (203528_at) CD163, (203645_s_at) PLA2G2A, (203649_s_at) CXCL9, (203915_at) CYBB, (203923_s_at) IRF8, (204057_at) CD48, (204118_at) TYROBP, (204122_at) GLIPR1, (204222_s_at) FCER1G, (204232_at) PLEKHO2, (204436_at) CD44, (204490_s_at) SLC7A7, (204588_s_at) STC1, (204595_s_at) CD52, (204661_at) VSIG4, (204787_at) IL10RA, (204912_at) SASH3, (204923_at) TLR2, (204924_at) CSTA, (204971_at) CCR1, (205098_at, 205269_at) LCP2, (205270_s_at) GZMA, (205488_at) CD86, (205685_at) CD8A, (205758_at) ITGAM, (205786_s_at) LY86, (205859_at) PTPN6, (206687_s_at) CCR2, FLJ78302, (206978_at) PTPRC, (207238_s_at) SYK, (207540_s_at) LILRB2, (207697_x_at) LCP1, (208885_at) CORO1A, (209083_at) HLA-DQB1, (209480_at) DLK1, (209560_s_at) CD44, (209835_x_at) SPP1, (209875_s_at) A1F1, (209901_x_at) C3AR1, (209906_at) CD300A, (209933_s_at) NCF2, (209949_at) LILRB2, (210146_x_at) TLR1, (210176_at) LAIR1, (210644_s_at) LILRB1, (211336_x_at) TRBC1, TRBC2, TRBV19; (211796_s_at) CD44, (212063_at) PTPRC, (212587_s_at, 212588_at) HLA-DQA1 HLA-DQA2; (212671_s_at) hCG — 1998957, HLA-DQB1/B2, HLA-DRB1/2/3/4/5; (21299_x_at) AIF1, (213095_x_at) DOCK2, (213160_at) HSPA6, (213418_at) RNASE6, (213566_at) RAC2, (213603_s_at) MYO1F, (213733_at) HLA-DQA1, (213831_at) LYZ, (213975_s_at) LOC648998, (214084_x_at) CD163, (215049_x_at) AIF1, (215051_x_at) ADA, (216705_s_at) FCGR1A, FCGR1C; (216950_s_at) GLUL, (217202_s_at) SNX10, (218404_at) MAFB, (218559_s_at) CCDC109B, (218802_at) BIN2, (219191_s_at) DOCK10, (219279_at) SLAMF8, (219386_s_at) SIGLEC1, (219519_s_at) 1-Mar, (219574_at) MS4A4A, (219607_s_at) MS4A6A, (219666_at) GAL3ST4, (219815_at) PSTPIP2, (219938_s_at) TLR7, (220146_at) COTL1, (221059_s_at) NPL, (221210_s_at) SH3BGRL3, (221269_s_at) PYCARD, (221666_s_at) CLEC7A, (221698_s_at) OBFC2A, (222872_x_at) CENTA2, (222876_s_at, 223343_at) MS4A7, (223344_s_at, 223343_at) MS4A6A, (224356_x_at) MS4A4A, (224357_s_at) COTL1, (224583_at) BCAT1, (225285_at) C1QC, (225353_s_at) CTSC, (225646_at) CTSC, (225647_s_at) BCAT1, (226517_at, 226818_at) MPEG1, (226841_at) FYB, (227266_s_at) RILPL2, (227983_at) OSR1, (228399_at) C1orf162, (228532_at) LILRB1, (230741_at) MRO, (231358_at) CTSS, (232617_at) DOCK8, (232843_s_at) OBFC2A, (233085_s_at) PARVG, (234987_at) CPM, (235019_at) HAVCR2, (235458_at) CCL18, (32128_at) CD52, (34210_at) MAFF, (36711_at) SIGLEC1; marker signature II: (1552411_at) DEFB106A/B, (1556721_at) FLJ33706, (1559224_at) LCE1E, (1562256_at, 1562257_x_at) NLRP1, (1562785_at) HERC6, (1564281_at) LOC285708, (1564362_x_at) ZNF843, (1569568_at) NA, (1569569_x_at) NA, (213609_s_at) SEZ6L, (213791_at) PENK, (224209_s_at) GDA, (231628_s_at) NA, (243909_x_at) GUSBL2, (244891_x_at) NA; marker signature III: MafB, MafF, MHC class II, CD44, BCAT1 ( Homo sapiens ); CCR2, BCAT1, ADA, Annexin II, Pleckstrin ( Homo sapiens ); p47-phox, CCR2, p67-phox, Pleckstrin, IL-12 receptor ( Homo sapiens ); C1q, CD44, CD14, SLAP-130(ADAP), alpha-4/beta-1 integrin ( Homo sapiens ); Plastin, IRT-1 ( Homo sapiens ); CD163, HP/HB complex ( Homo sapiens ); Complement component C1, Complement C4=Complement component C4a + , Complement component C4b, Complement C2=Complement component C2a + , Complement component C2b, PLTP, ABCA1, CREB1, Cholesterol extracellular region, Cholesterol+ATP+H 2 O=Cholesterol+ADP+PO 4 3− ( Homo sapiens ); marker signature IV: (210667_at) AQP4, (221212_x_at) PBRM1, (227145_at) LOXL4, (228329_at) DAB1, (231577_s_at) GBP1, (231906_at) HOXD8, (235334_at) ST6GALNAC3, (237783_at) PLAC8L1; marker signature V: (1552974_at) NA, (1553781_at) ZC3HAV1L, (1554478_a_at) HEATR3, (1556760_a_at) NA, (1556883_a_at) LOC440896, (1557717_at) LOC338862, (1560144-at) NA, (1560683_at) BCL8, (1560684_x_at) BCL8, (1561543_at) NA, (1562035_at) NA, (1563054_at) NA, (1563452_at) K1AA0241, (1564107_at) NA, (1564733_at) NA, (1565788_at) NA, (1566550_at) NA, (1568589_at) NA, (201291_s_at) TOP2A, (204666_s_at) RP5-1000E10.4, (208356_s_at) BCL2L11, (209371_s_at) SH3BP2, (215512_at) 6-Mar, (216947_at) DES, (217292_at) MTMR7, (218554_s_at) ASH1L, (218585_s_at) DTL, (219528_at) TIPIN (219735_s_at) TFCP2L1, (219918_s_at) ASPM, (220085_at) HELLS, (220735_s_at) SENP7, (220930_s_at) MGC5590, (221212_x_at) PBRM1, (221268_s_at) SGPP1, (221969_at) NA, (223700_at) MND1, (223865_at) SOX6, (224424_x_at) LOC440888, (224426_s_at) LOC440888, (232453_at) NA, (233786_at) NA, (235588_at) ESCO2, (235661_at) NA, (2358990 CA13, (236628_at) NA, (236470_at) NA, (237289_at) CREB1, (238370_x_at) RPL22, (238375_at, 239486_at) NA, (239899_at) RNF145, (241922_at) NA, (242784_at) NA, (242939_at) TFDP1, (244356_at) NA, (244609_at) NA, (37892_at) COL11A1, marker signature VI: (1553972_a_at) CBS, (1557833_at) NA, (1560395_at) NA; (201909_at) LOC100133662, RPS4Y1; (204409_s_at, 204410_at) EIF1AY, (205000_at, 205001_s_at) DDX3Y; (205033_s_at) DEFA1, DEFA3, LOC728358; (205048_s_at) PSPH, (205609_at) ANGPT1, (206624_at) LOC100130216, USP9Y; (206700_s_at) JARID1D, (207063_at) CYorf14, (208067_x_at) LOC100130224, UTY; (209771_x_at) CD24, (211018_at) LSS, (211149_at) LOC100130224, UTY; (212768_s_at) OLFM4, (212816_s_at) CBS, (212906_at) GRAMD1B, (214131_at) CYorf15B, (214218_s_at) XIST, (214983_at) TTTY15, (216758_at) NA, (219938_s_at) PSTPIP2, (221728_x_at) XIST, (223645_s_at, 223646_s_at) CYorf15B, (224293_at) TTTY10, (224588_at, 224589_at, 224590_at, 227671_at) XIST, (227742_at) CLIC6, (228194_s_at) SORCS1, (228492_at) LOC100130216, USP9Y; (221960_at) MUM1L1, (229534_at) ACOT4, (230104_s_at) TPPP, (230760_at) LOC100130829, ZFY; (231592_at) TSIX, (232365_at) SIAH1, (232618_at) CYorf15A, (233176_at) NA, (235334_at) ST6GALNAC3, (235446_at) NA, (235942_at) LOC401629, LOC401630, (236694_at) CYorf15A, (239568_at) PLEKHH2, (239584_at) NA, (239677_at) NA, (24316_at) NA, (243610_at) C9orf135, (244482_at) Na, (226_s_at) CD24; marker signature VII: (1552946_at) ZNF114, (1553607_at) C21orf109, (1555485_s_at) FAM153B, (1558882_at) LOC401233, (1561012_at) NA, (1566518_at) NA, (1569539_at) NA, (1569794_at) NA, (207781_s_at) ZNF711, (222375_at) NA, (229288_at) NA, (229523_at) TTMA, (235803_at) NA, (238553_at) EPHA7, (238755_at) NA, (240783_at) NA, (240903_at) NA, (242641_at) NA, (243012_at) NA, (244626_at) NA, (244636_at) NA; marker signature VIII: (156328_at) NA, (204477_at) RABIF, (20275_at) GTPBP1, (214313_s_at) EIF5B; marker signature IX: (20447_at) RABIF, (205275_at) GTPBP1, (214313_s_at) EIF5B, (224500_s_at) MON1A, (236093_at) NA, (243564_at) PDE1C; marker signature X: (156328_at) NA, (205275_at) GTPBP1, (207300_s_at) F7, (214313_s_at) EIF5B, (214473_x_at) PMS2L3, (227509_x_at) NA, (228232_s_at) VSIG2, (230731_x_at) ZDHHC8, (232586_x_at) LOC100133315, (236093_at) NA, (237867_s_at) PID1, (243564_at) PDE1C; marker signature XI: (1556205_at) NA, (202179_at) BLMH, (203134_at) PICALM, (203540_at) GFAP, (205554_s_at) DNASE1L3, (205673_s_at) ASB9, (205794_s_at) NOVA1, (209220_at) GPC3, (209304_x_at) GADD45B, (209540_at) IGF1, (209923_s_at) BRAP, (212173_at) AK2, (213469_at) LPPR4 (214338_at) DNAJB12, (216269_s_at) ELN, (217950_at) NOSIP, (218180_s_at) EPS8L2, (220117_at) ZNF385D, (220941_s_at) C21orf91, (222002_at) C7orf26, (222879_s_at) POLH, (223574_x_at) PPP2R2C, (223586_at) ARNTL2, (230974_at) DDX19B, (233298_at) C13orf38, SOHLH2; (238151_at) NA, (243076_x_at) GLI4; marker signature XII: (1553894_at) CCDC122, (1557311_at) LOC100131354, (1557996_at) POLR2J4, (1558430_at) NA, (1559227_s_at) VHL, (1561789_at) NA, (1569312_at) NA, (205238_at) CXorf34, (211734_s_at) FCER1A, (218699_at) RAP2C, (225207_at) PDK4, (231114_at) SPATA22, (231418_at) NA, (231819_at) NA, (231956_at) KIAA1618, (233927_at) NA, (239151_at) CTGLF6, (241788_x_at) NA, (242691_at) NA; marker signature XIII: (1552302_at) FLJ77644, TMEM106A; (1552310_at) C15orf40, (1553212_at) KRT78, (1555349_a_at) ITGB2, (1555878_at) RPS24, (1556033_at) NA, (1556507_at) NA, (1558605_at) NA, (1559221 at) LCE1E, (1562785_at) HERC6, (1565662_at) NA, (1565830_at) NA, (202375_at) SEC24D, (202445_s_at) NOTCH2, (203741_s_at) ADCY7, (204222_s_at) GLIPR1, (206052_s_at) SLBP, (206333_at) MSI1, (206770_s_at) SLC35A3, (209307_at) SWAP70, (211089_s_at) NEK3, (211341_at) LOC100131317, POU4F1; (212511_at) PICALM, (212830_at) MEGF9, (212999_x_at) hCG — 1998957, HLA-DQB1/2, HLA-DRB1/2/3/4/5; (213501_at) ACOX1, (213831_at) HLA-DQA1, (217054_at) NA, (217182_at) MUC5AC, (217322_x_at) NA, (217777_s_at) PTPLAD1, (218803_at) CHFR, (219425_at) SULT4A1, (221663_x_at) HRH3, (223077_at) TMOD3, (224327_s_at) DGAT2, (224996_at) Na, (225579_at) PQLC3, (226240_at) MGC21874, (227280_s_at) CCNYL1, (227618_at) Na, (227983_at) RILPL2, (228980_at) RFFL, (229191_at) TBCD, (230836_at) ST8SIA4, (231599_x_at) DPF1, (234495_at) KLK15, (234986_at) NA, (234987_at) NA, (236232_at) STX4, (236404_at) NA, (236698_at) NA, (238327_at) LOC440836, (238445_x_at) MGAT5B, (239463_at) NA, (242383_at) NA, (242563_at) NA, (243819_at) NA, (244841_at) SEC24A, (32069_at) N4BP1, (44673_at) SIGLEC1, (53720_at) C19orf66; marker signature XIV: MSI1 (1556507_at), KRT78, KRT78 (1556507_at), KRT78 (1556507_at), 1556507_at; marker signature XV: (201721_s_at) CD14, (1554899_s_at) FCER1G, (210146_x_at) TLR1, (204923_at) TLR2, (1555349_a_at) ITGB2, (44673_at) SIGLEC1, (219938_s_at) TLR7, (203741_s_at) ADCY7, (212830_at) MEGF9, (21777_s_at) PTPLAD1, (209307_at) SWAP70, (206333_at) MSI1, (1559224_at) LCE1E; or combinations thereof.
28 . A transcriptomic biomarker for diagnosing one or more cardiac diseases or disorders comprising one or more marker signatures of claim 26 .
29 . A method of diagnosing myocarditis and other cardiac diseases or disorders, comprising:
identifying in a biological sample from a patient a molecular signature set forth in Tables 1 to 19, complementary sequences, fragments, alleles, variants and gene products thereof; assessing the probability of identification of each component in each sample; assigning each to a class; and, diagnosing myocarditis and other cardiac disorders.
30 . A method of diagnosing heart disease or myocarditis comprising:
identifying in a biological sample from a patient a molecular signature set forth in Tables 1 to 19, complementary sequences, fragments, alleles, variants and gene products thereof; assessing the probability of identification of each component gene in each sample; assigning each to a class; and, diagnosing heart disease or myocarditis.
31 . A kit comprising a transcriptomic biomarker of any one or more molecular signatures set forth in Tables 1 to 19.
32 . A cell expressing any one or more biomolecules selected from Tables 1 to 19.
33 . A vector encoding any one or more biomolecules selected from Tables 1 to 19.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.